- Report
- October 2024
- 189 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- November 2024
- 150 Pages
Global
From €5656EUR$5,950USD£4,752GBP
- Drug Pipelines
- November 2023
- 30 Pages
United States
From €2614EUR$2,750USD£2,196GBP
- Report
- April 2024
- 132 Pages
Global
From €903EUR$950USD£759GBP
Within the context of over-the-counter (OTC) drugs, intravenous paracetamol, also known as acetaminophen, occupies a specialized niche. While paracetamol in oral forms, such as tablets or liquids, is widely available without a prescription and well-used for treating pain and fever, its intravenous counterpart is typically used in clinical settings. Intravenous paracetamol is reserved for administering to patients who are unable to take oral medication, offering a rapid onset of pain relief or fever control. It is commonly utilized in hospitals for postoperative pain management or when precise dosage control is necessary. The distinction between the general OTC products and intravenous formulations is marked by the latter's requirement for medical supervision and administration.
Some companies that produce or distribute intravenous paracetamol include Pfizer, which has a portfolio of pharmaceutical products that spans a variety of delivery methods, including intravenous solutions. Baxter International is another player in this market, providing medically essential products, including injectable drugs. Another notable company is Fresenius Kabi, a healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion, and clinical nutrition, which includes intravenous paracetamol in its lineup. Show Less Read more